The JAK2 46/1 haplotype (GGCC) in myeloproliferative neoplasms and splanchnic vein thrombosis: a pooled analysis of 26 observational studies.

ABSTRACT

Numbers of observational studies suggest that the JAK2 46/1 (GGCC) haplotype may increase the risk of myeloproliferative neoplasms (MPNs) and splanchnic vein thrombosis (SVT), but the results remain controversial. We aimed to examine the association between the JAK2 46/1 haplotype and risk of MPNs and SVT by conducting a meta-analysis. PubMed, EMBASE, Cochrane Library, CBM, and CNKI databases were searched to identify eligible studies without restrictions and by reviewing reference lists of obtained articles. Both fixed and random-effects models were used to calculate the summary risk estimates. We identified 26 observational studies of the JAK2 46/1 haplotype and risk of MPNs and SVT involving 8,561 cases and 7,434 participants. In the overall analysis, it was found that the JAK2 46/1 haplotype significantly elevated the risk of MPNs (rs10974944 C vs T odds ratio (OR) = 2.19, 95 % confidence interval (CI) = 1.86-2.57, P < 0.0001; CC vs TT OR = 4.63, 95 % CI = 3.32-6.47, P < 0.0001; CT vs TT OR = 2.49, 95 % CI = 2.11-2.95, P < 0.0001; (CC + CT) vs TT OR = 2.92, 95 % CI = 2.51-3.39, P < 0.0001; rs12343867 C vs T OR = 1.88, 95 % CI = 1.59-2.22, P < 0.0001; CC vs TT OR = 3.16, 95 %CI = 2.14-4.65, P < 0.0001; CT vs TT OR = 2.04, 95 % CI = 1.51-2.74, P < 0.0001; (CC + CT) vs TT OR = 2.25, 95 % CI = 1.73-2.95, P < 0.0001) and SVT (C vs T OR = 1.27, 95 % CI = 1.06-1.52, P = 0.011; CC vs TT OR = 2.33, 95 % CI = 1.42-3.81, P = 0.001; (CC + CT) vs TT OR = 1.25, 95 % CI = 1.02-1.53, P = 0.034). There was no evidence of a significant association between the rs12343867 and the risk of SVT in the genetic model (CT vs TT OR = 1.01, 95 % CI = 0.80-1.29, P = 0.906). This meta-analysis provides new evidence supporting the conclusion that the JAK2 46/1 haplotype enrichment is significantly associated with the development of MPNs and SVT in these patients.